The prognostic value and clinicopathological significance of CD44 expression in ovarian cancer: a meta-analysis

Zhao, Lei; Gu, Chenglei; Zhang, Zhe; Ye, Mingxia; Fan, Wensheng; Han, Weidong; Meng, Yuanguang

doi:10.1007/s00404-016-4137-3

Cited by 15 publications

(9 citation statements)

References 40 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD44 is the hyaluronate receptor and is important in adhesion. In ovarian cancer CD44 correlates with chemoresistance and tumor progression [74][75][76] . One function of CD44 is to activate Stat3 77 .…”

Section: Cell Surface Markersmentioning

confidence: 99%

Can Stemness and Chemoresistance be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer?

Roy

Dahl²

2018

Preprint

View full text Add to dashboard Cite

Ovarian cancer is the most lethal gynecological malignancy. Poor overall survival, particularly for patients with high grade serous (HGS) ovarian cancer, are often attributed to late stage at diagnosis and relapse following chemotherapy. HGS ovarian cancer is a heterogenous disease in that few genes are consistently mutated between patients. Additionally, HGS ovarian cancer is characterized by high genomic instability. For these reasons personalized approaches may be necessary for effective treatment and cure. Understanding the molecular mechanisms that contribute to tumor metastasis and chemoresistance are essential to improve survival rates. One favored model for tumor metastasis and chemoresistance is the cancer stem cell (CSC) model. CSCs are cells with enhanced self-renewal properties that are enriched following chemotherapy. Elimination of this cell population is thought to be a mechanism to increase therapeutic response. Therefore, accurate identification of stem cell populations that are most clinically relevant is necessary. While many CSC identifiers (ALDH, OCT4, CD133, and side population) have been established, it is still not clear which population(s) will be most beneficial to targeted in patients. Therefore, there is a critical need to characterize CSCs with reliable markers and find their weaknesses that will make the CSCs amenable to therapy. Many signaling pathways are implicated for their roles in CSC initiation and maintenance. Therapeutically targeting pathways needed for CSC initiation or maintenance may be an effective way of treating HGS ovarian cancer patients. In conclusion, the prognosis for HGS ovarian cancer may be improved by combining CSC phenotyping with targeted therapies for pathways involved in CSC maintenance.

show abstract

Section: Cell Surface Markersmentioning

confidence: 99%

Can Stemness and Chemoresistance be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer?

Roy

Dahl²

2018

Preprint

View full text Add to dashboard Cite

show abstract

“…CD44s is more highly expressed by EMT CSCs, and CD44v is more highly expressed by non-EMT CSCs (14, 18). CD44 or CD44v6 expression has been shown to be correlated with poor overall survival (OS) in gastric cancer (19), but CD44 or CD44v6 expression has been found to not be correlated with OS in ovarian cancer (20); these findings suggest that some prognostic information regarding CD44 is still conflicting.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Value of CD44 and Its Isoforms in Advanced Cancer: A Systematic Meta-Analysis With Trial Sequential Analysis

Han

Huang

et al. 2019

Front. Oncol.

View full text Add to dashboard Cite

Objective: Cancer stem cell marker CD44 and its variant isoforms (CD44v) may be correlated with tumor growth, metastasis, and chemo-radiotherapy resistance. However, the prognostic power of CD44 and CD44v in advanced cancer remains controversial. Therefore, the purpose of our study was to generalize the prognostic significance of these cancer stem cell markers in advanced cancer patients.Methods: Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated from multivariable analysis to assess the associations among CD44, CD44v6, and CD44v9 positivity and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Trial sequential analysis (TSA) was also conducted.Results: We included 15 articles that reported on 1,201 patients with advanced cancer (CD44: nine studies with 796 cases, CD44v6: three studies with 143 cases, and CD44v9: three studies with 262 cases). CD44 expression was slightly linked to worse OS (HR = 2.03, P = 0.027), but there was no correlation between CD44 expression and DFS, RFS, or PFS. Stratified analysis showed that CD44 expression was not correlated with OS at ≥5 years or OS in patients receiving adjuvant therapy. CD44v6 expression was not associated with OS. CD44v9 expression was closely associated with poor 5-years CSS in patients treated with chemo/radiotherapy (HR = 3.62, P < 0.001). However, TSA suggested that additional trials were needed to confirm these conclusions.Conclusions: CD44 or CD44v9 might be novel therapeutic targets for improving the treatment of advanced cancer patients. Additional prospective clinical trials are strongly needed across different cancer types.

show abstract

“…Restraining CD44 gene expression could markedly inhibit the growth of ovarian cancer cells, suppress tumor angiogenesis, and reduce tumor recurrence and metastasis [24]. Typically, ovarian cancer patients with high CD44 expression showed high chemoresistance [25]. Additionally, CD44 knockout ovarian cancer mice had markedly lowered cell proliferation, migration, and invasion capacities, but with enhanced drug sensitivity [26].…”

mentioning

confidence: 99%

Biological Characteristics and Carrier Functions of Pegylated Manganese Zinc Ferrite Nanoparticles

Guo

Dou

Lin

et al. 2019

Journal of Nanomaterials

View full text Add to dashboard Cite

This study was performed to investigate the biocompatibility (BC), magnetothermal effect, and DNA binding biological characteristics of manganese zinc ferrite nanoparticles (Mn0.6Zn0.4Fe2O4-NPs (MZF-NPs)) coated with pegylated manganese (PEG-MZF-NPs). Their functions as gene transfer carrier for gene therapy and magnetic medium for tumor hyperthermia were also explored. The manganese zinc ferrite nanoparticles were synthesized through high temperature cracking, and their characterizations were discovered. Hemolysis test and MTT assay were performed to evaluate biocompatibility, and their self-heating effects in the alternating magnetic field were investigated. PEG-MZF-NPs with different concentrations were measured by using 7.0 T Micro-MR scanner (MRI) to calculate the T2 value and r2 relaxation rate of each sample. The CD44-shRNA plasmids were constructed, and their ability to bind PEG-MZF-NPs were examined. The DNA release from PEG-MZF-NP/DNA complex and protection of DNA from nuclease digestion were also detected. After CD44-shRNA-EGFP were transfected into the ovarian cancer SK-OV-3 cells by using PEG-MZF-NPs as carriers, the transfection efficiency was detected by a flow cytometer and expression of CD44 mRNA and protein in cells was detected using RT-PCR and Western blot, respectively. We successfully prepared PEG-MZF-NPs with favorable dispersity, magnetic responsiveness, and BC. Typically, the excellent magnetothermal effect can be used for a tumor magnetothermal therapeutic study. In vitro MRI showed the application potential for being magnetic resonance T2 relaxation contrast agents and the possibility to achieve goal of integration of targeting diagnosis and treatment. The CD44-shRNA plasmids have been successfully constructed and concluded that PEG-MZF-NPs may serve as gene transfer carriers for gene therapy.

show abstract

The prognostic value and clinicopathological significance of CD44 expression in ovarian cancer: a meta-analysis

Cited by 15 publications

References 40 publications

Can Stemness and Chemoresistance be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer?

Can Stemness and Chemoresistance be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer?

Prognostic Value of CD44 and Its Isoforms in Advanced Cancer: A Systematic Meta-Analysis With Trial Sequential Analysis

Biological Characteristics and Carrier Functions of Pegylated Manganese Zinc Ferrite Nanoparticles

Contact Info

Product

Resources

About